# Healthcare Podcast Weekly Digest: April 7–13, 2026 > A podcast-sourced healthcare digest for the week of April 7–13, 2026. Oral GLP-1 launches, a generous CMS rate hike for managed care, and a record M&A pace dominate the tape as biotech outperforms. ## Healthcare Podcast Weekly Digest ### Week of April 7–13, 2026 --- ```request-access variant: ghost heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## This Week's Big Picture Biotech is outperforming everything. XBI is up 8% YTD against a flat S&P 500 and a negative NASDAQ, with a trailing 12-month return of +84%. The week's dominant themes: the oral GLP-1 wars kicked off in earnest with simultaneous launches from **Novo** and **Lilly**, a surprisingly generous CMS rate hike juiced managed care stocks, and healthcare M&A reached a pace that could make 2026 a record year. Meanwhile, tariffs turned out to be mostly noise for large-cap pharma, but could be an existential squeeze on smaller companies. --- ## 👥 Key People This Week | Who | Affiliation | What They Said | | --- | --- | --- | | Dr. Roderick Wong | CIO, RTW Investments | Called this "the most exciting time in drug discovery" in his 20+ year career. Forecasts "a new wave of commercially successful biotech companies... of the size that we haven't seen ever." | | Josh Schimmer | Analyst, Biotech Hangout | Argues biotech profitability inflection, not pharma M&A, will be the real catalyst: companies transitioning to "meaningful cash flows" will draw generalist capital that "is going to have a much more meaningful impact on the sector." | | Michael Yee | Analyst | Favors large-cap pharma at "9-15x earnings" as "an attractive place to be this year," noting drug pricing headwinds are "out of the way." | | Steve Usdin | BioCentury | Warned that tariffs are "squeezing midsize and smaller companies" who can't offer onshoring commitments, giving large pharma "leverage in acquiring assets from smaller companies that rely on overseas manufacturing." | | Sam Fazeli | Analyst | Dismissed tariff impact as "much more about form over substance... The market hardly blinked." | | Dave Knapp | On The Pen podcast | Sounded the alarm on Foundayo liver safety: "If that signal actually shows up in the real world... it is going to tarnish the entire category of medications." | | Dr. Jacque Sokolov | SSB Solutions | Warned against buying managed care: "I wouldn't be jumping to buy PBMs or anything that is a heavy pre-authorization component right now." | | Oliver Barnes | Analyst | On M&A pricing: "Sellers not necessarily looking for unreasonable premiums," signaling a buyer-friendly deal market. | | Casey Hite | CEO, Aeroflow Health | On tariff pain for smaller healthcare companies: "The initial size of the tariffs... would have made some business lines unsustainable. We would have had to exit them completely." | --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## 🔥 Hot Topics ### 1. The Oral GLP-1 Wars Have Begun The biggest product launches of the year happened simultaneously. Combined 2025 injectable GLP-1 revenues for Lilly and Novo hit $25.5 billion, and the oral market is now live: - **Novo's oral Wegovy** launched April 7 at $399/month self-pay. ~16% weight loss in trials, but requires empty-stomach dosing with a 30-minute food restriction. - **Lilly's Foundayo** launched April 9 at $149-$349/month. ~11% weight loss, no food restrictions. - Consensus year-1 U.S. estimates: ~$1.75B for Foundayo, ~$1.5B for oral Wegovy (~$3.5B combined). - Viking CEO Brian Leanne noted oral launches are expanding the market, not cannibalizing injectables: "Most of those people are new to therapy." - The global addressable obesity market could reach $190 billion by 2035 per Simon Erickson (7investing). But there's a cloud over Foundayo. FDA mandated post-marketing studies on potential liver injury (DILI), cardiovascular risks, and gastric emptying. Lilly said "there have been no indications of liver damage in late-stage testing." Note: Pfizer previously abandoned danuglipron (its oral GLP-1 candidate) due to liver toxicity. Lilly itself reduced orforglipron's max dose three times, from 45mg to 36mg to 17.2mg, "presumably for safety." Dave Knapp's warning is worth hearing: "The public is not ever going to separate small molecule GLP-1 from peptide GLP-1. If something comes back on this liver signal, it is going to tarnish the entire category of medications." Meanwhile, Chinese competition is accelerating. Innovent Biologics' IBI3032 achieved 10% weight loss within four weeks in Phase 1, claimed as the first oral small-molecule GLP-1R agonist at that level. ### 2. CMS Delivers a Gift to Managed Care CMS finalized 2027 Medicare Advantage rates at a 2.48% increase (~$13 billion in additional payments), dramatically better than the proposed 0.09%. Including risk score growth, the effective increase is ~5%. Humana led S&P gains; UNH rose 10% in a single session. **The bull case:** Andrew Horowitz (DHUnplugged) had positioned UNH as a double-allocation pick in January. "Our thesis was solid... and it played out." Goldman Sachs expects UNH and CVS to anchor Q1 commentary around "confidence in driving margin expansion on a multi-year basis." **The bear case:** David Meyers (Brown University) noted MA plans are overpaid "anywhere from 5 to 20 percent more than they should be relative to traditional Medicare." CMS is implementing a ~6% coding pattern adjustment because "MA plans systematically document patients as sicker." Kaiser Permanente just settled with DOJ for >$500 million on upcoding. And the 2.48% is still "about half of what they got last year in terms of a dollar amount overall." **ACA enrollment cracks:** One in seven ACA enrollees (~14%) failed to pay their first bill for 2026 coverage. In some states, 25%+. Normal early-year drop-off is mid-single digits. This is a developing risk for CVS, Centene, Cigna, Elevance, Humana, Molina, and UNH. ### 3. M&A at Record Pace Q1 2026 saw 41 deals worth $54.88 billion, up 19% from Q4 2025. Seven billion-dollar takeouts between March 20 and April 14 totaled >$28B upfront. BMO Capital Markets projects 2026 could reach a record $172 billion in deals >$500M. Key deals this week: - **Gilead/Tubulis $3.15B:** Gilead's third multi-billion acquisition of 2026. Adds ADC technology and pipeline. Plans to keep Tubulis intact as an ADC research unit in Munich. - **Neurocrine/Soleno ~$3B:** Soleno sold below its $4B+ peak valuation. Oliver Barnes: "The fact that the board and management were willing to transact at a lower price... shows we've got this very ripe market where there are lots of active buyers and sellers not necessarily looking for unreasonable premiums." - **Merck/Terns $6.7B:** SEC filing revealed Merck initially offered $61/share, then lowered to $50 after accessing updated Cardinal study data showing degraded efficacy, settling at $53. Analyst Sivanovich: "If Terns had remained independent... this could have been potentially catastrophic for the stock." - **Biogen/Apellis $5.6B:** Paid ~4.7x peak sales. Stock fell 5% on announcement. Competitive risks from Nexon and Regeneron data later in 2026. Predicted next acquirers: Amgen, AbbVie, Bristol-Myers Squibb, Novartis (per BMO). ### 4. Revolution Medicines, Data of the Year? Revolution Medicines (RVMD) reported data showing "a doubling of survival in advanced pancreatic cancer" with its RAS inhibitor Diraxon-Rasib. Shares rose ~40%. FDA granted a commissioner's priority review voucher. BioSpace's McKenzie: "This truly may go down as the most exciting clinical trial results of the entire year." --- ## ⚖️ Key Debates **Debate 1: Is Eli Lilly Worth 50x Free Cash Flow?** - *Bull:* Dominant GLP-1 franchise, ~40% revenue growth trajectory, diversifying pipeline, oral launch expands TAM. - *Bear:* Jason (Telltales) notes Lilly trades at "almost 50 times free cash flow, more expensive than NVIDIA at 40 times," with barriers to entry "lower than that of semiconductors." And "a blockbuster, multibillion-dollar drug can go to zero overnight." **Debate 2: Tariffs, Form Over Substance or SMID-Cap Squeeze?** - *For large-cap:* 16 of 17 major pharma companies signed MFN deals and are exempt. ~$400B in onshoring commitments already secured. Market "hardly blinked." - *For small/mid-cap:* Mid-size companies "in a much worse position to do deals" and can't offer manufacturing expansions. Aeroflow's Casey Hite: tariffs would have made "some business lines unsustainable." The tariff regime structurally tilts the playing field toward large pharma as both acquirers and survivors. **Debate 3: Managed Care, Buying Opportunity or Value Trap?** - *Buy:* CMS rate hike removes near-term overhang. UNH positioning for multi-year margin expansion. CVS poised to dominate pharmacy retail as Rite Aid and Walgreens exit. - *Avoid:* Structural overpayment of 5-20%, ongoing upcoding enforcement (Kaiser $500M+ DOJ settlement), ACA enrollment cracks, and Dr. Sokolov's warning about "serious foundational issues" around prior authorization complexity. **Debate 4: What Drives Biotech Rerating, M&A or Profitability?** - *M&A camp:* Record deal pace gives every clinical-stage company acquisition optionality. - *Profitability camp (Schimmer):* Generalist capital flowing in because companies are reaching "meaningful cash flows," which matters more for sector-wide rerating than individual takeouts. **Debate 5: FDA Predictability, Overhang Lifting or Still Uncertain?** - Vinay Prasad's departure and new CRL review processes are positive signals. But Replimune's second CRL on RP1 shows the approval bar remains unclear. Schimmer: "We're still trying to figure out exactly where the bar is set on a case by case basis." --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## 🌱 Emerging Themes **1. Blood-Brain Barrier Platforms Are Having Their Moment** Roche's trontinumab showed 75% of Alzheimer's patients reaching A-beta plaque negative within six months with a fraction of the ARIA seen with naked antibodies. Denali received approval for its transferrin shuttle (Hunter disease). AbbVie acquired Aliotta for $1.4B; Novartis in-licensed Sineuro's platform ($165M upfront, $1.5B biobucks). This is moving from science project to validated platform. **2. Radioligand Therapy Is Scaling** Three FDA-approved drugs, ~100 in clinical trials. Richard Patton (Courage Capital) is investing in dedicated outpatient radioligand clinics (United Theragnostics) with 18-month profitability per clinic and 3-year payback. Infrastructure buildout is the investable angle here. **3. AI as Margin Defense in Healthcare Services** Casey Hite (Aeroflow) detailed AI deployment for medical record extraction, customer inquiry agents, and developer productivity tools automating 20-30% of initial software development. His observation: "Tariffs have shook things up and have really accelerated companies and people embracing technology that had already existed." **4. Generalist Capital Returning to Biotech** Stephen Hansen (BioCentury): generalists "have been underweight our sector for so long" that biotech companies proposing $400M raises are now closing $650M. This is a flow-driven theme that could sustain the rally independent of fundamentals. **5. Pharma Companies Delaying European Launches** To avoid setting reference prices that could be used under U.S. MFN pricing, some pharma companies are "considering either delaying launches or not launching at all in Europe." Annalie Armstrong (BioSpace) called this "shaking" and contrary to "the spirit of innovation and helping patients." If this trend accelerates, it's a major policy unintended consequence. **6. Non-Animal Testing Gets FDA Backing** FDA proposed allowing substitution of non-animal models for some traditional animal testing in first-in-human trials. Steve Usdin: "What FDA is attempting is really a more transformative shift by redefining the evidence that's required for trial initiation." But "needs a lot more scientific validation" and "would take years before it's fully operational." --- ## 📋 Regulatory Watch - **Foundayo post-marketing:** FDA requiring liver injury (DILI), cardiovascular, gastric emptying, and lactation studies. - **CMS MA rates:** 2.48% finalized for 2027, ~5% effective with risk score growth. ~6% coding pattern adjustment applied. - **Vinay Prasad** departing FDA by end of April. Companies with CRLs meeting with FDA chief counsel, "highly unusual" but positive. - **ACIP overhaul:** HHS Secretary RFK Jr. replaced all 17 ACIP members. Court ruled it violated the charter. States and the American Pediatric Association now making independent vaccine recommendations. - **PDUFA reauthorization:** Proposed ~$2M fee reduction for U.S.-based first-in-human trials (down from initial $10M penalty for non-U.S. trials). Usdin: "Too small to meaningfully influence company behavior." - **CRL transparency:** FDA publishing complete response letters since July 2025. Heavy redactions limit full transparency but analysts "definitely happy with the new policy." --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## 🎯 Week Ahead, What to Watch - **JNJ Q1 earnings** (reported April 15): Revenue $24.1B, modest beat. Watch for Icotide (plaque psoriasis) commentary; CEO Duato called it potentially "one of the largest products ever for J&J." - **Foundayo real-world safety monitoring:** Any early signals on liver toxicity will move the entire oral GLP-1 space. - **Regeneron MFN deal:** Only major pharma holdout. Expected to announce "in the near future." - **ACA enrollment data:** More states reporting payment drop-off rates. Watch for managed care guidance revisions. - **Healthcare earnings season ramping:** UNH (April 17), ABT (April 16), JNJ follow-up analyst calls. --- ## Sources Biotech Hangout Ep. 178-179, BioCentury Ep. 359-360, Insightful Investor, BioSpace Podcasts, Citeline Podcasts, On The Pen, Telltales, 7investing, DHUnplugged, Squawk on the Street, A Health Podyssey, Becker's Healthcare, Off the Chart, The Capital Raiser Show, The Biltmore View, Raising Biotech, thefly.com, Reuters, WSJ. ```request-access variant: banner heading: Run your own corpus. description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage. buttonText: Request access ```